The latest iteration of the combat-proven APG-82 radar incorporates gallium nitride (GaN) technology to enhance the radar's effectiveness and ...

Sharma indicated the company expects to "complete enrollment with 62 to 65 patients across a wide range of solid tumors by the June 2025" for the LP-184 Phase 1a trial, with comprehensive data ...

CEO Panna Sharma stated that "the first quarter of 2025 represents a pivotal inflection point for Lantern Pharma." He highlighted significant progress in the clinical portfolio and the expansion of ...